ABEO Abeona Therapeutics, Inc.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Company profile

Ticker

ABEO

Exchange

NASDAQ

Website

www.abeonatherapeutics.com

CEO

Joao Siffert

Incorporated in

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Generic

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Teva Pharmaceutical Industries • Bristol Myers Squibb • ELI LILLY & Co • Warner Chilcott • AbbVie ...

Former names

Access Pharmaceuticals Inc, Chemex Pharmaceuticals Inc, Plasmatech Biopharmaceuticals Inc

SEC CIK

0000318306

Corporate docs

Articles of Incorporation & Bylaws

IRS number

830221517

ABEO stock data

S&P 500

1M 1Y 2Y 5Y

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings

Securities sold

Number of investors

Company financial data Financial data

Chart ABEO financial data

Quarter (USD)	Mar 20	Dec 19	Sep 19	Jun 19
Revenue				0
Net income	-48.16M	-16.43M	-17.37M	-23.92M
Diluted EPS	-0.52	-0.3	-0.35	-0.49
Operating income	-48.21M	-16.41M	-17.65M	-23.98M
Net change in cash	-89.1M	81.34M	5.31M	16.69M
Cash on hand	40.16M	129.26M	47.92M	42.61M
Cost of revenue

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue		3M	837K	889K
Net income	-76.28M	-56.67M	-27.32M	-21.87M
Diluted EPS	-1.51	-1.19	-0.66	-0.64
Net profit margin		-1890%	-3264%	-2460%
Operating income	-77.09M	-58.17M	-27.84M	-23.88M
Net change in cash	110.51M	-119M	68.61M	29M
Cash on hand	129.26M	18.75M	137.75M	69.14M
Cost of revenue

Financial data from company earnings reports

Recent insider trades

ABEO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	$Price	#Shares	$Value	#Remaining
20 May 20	Buono Stefano	Common Stock	Grant	Aquire A	0	17,969	0	287,969
20 May 20	Buono Stefano	Stock Option Common Stock	Grant	Aquire A	3.2	21,518	68.86K	21,518
20 May 20	Howell Stephen B.	Common Stock	Grant	Aquire A	0	17,969	0	97,463
20 May 20	Howell Stephen B.	Stock Option Common Stock	Grant	Aquire A	3.2	21,518	68.86K	21,518
20 May 20	Carr Edward	Common Stock	Grant	Aquire A	0	40,000	0	53,554
20 May 20	Carr Edward	Employee Stock Option Common Stock	Grant	Aquire A	3.2	28,919	92.54K	28,919
20 May 20	Siffert Joao MD	Common Stock	Grant	Aquire A	0	100,000	0	100,000
20 May 20	Siffert Joao MD	Employee Stock Option Common Stock	Grant	Aquire A	3.2	72,296	231.35K	72,296
20 May 20	Rouhandeh Steven H	Common Stock	Grant	Aquire A	0	120,000	0	495,000
20 May 20	Rouhandeh Steven H	Employee Stock Option Common Stock	Grant	Aquire A	3.2	86,756	277.62K	86,756

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

ABEO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0	NaN%
Opened positions	0	0	NaN%
Closed positions	0	0	NaN%
Increased positions	0	0	NaN%
Reduced positions	0	0	NaN%

13F shares	Current	Prev Q	Change
Total value	0	0	–
Total shares	0	0	–
Total puts	0	0	–
Total calls	0	0	–
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Fibrocell Science • Soligenix • DARA BioSciences • Voyager • Jazz Pharmaceuticals • Alder Biopharmaceuticals • Synedgen • AVAXIA BIOLOGICS • Galera Therapeutics • uniQure

Management Discussion

Total research and development spending for the first quarter of 2020 was $6.8 million, as compared to $11.7 million for the same period of 2019, a decrease of $4.9 million. The decrease in expenses was primarily due to:
Total general and administrative expenses were $6.4 million for the first quarter of 2020, as compared to $5.7 million for the same period of 2019, an increase of $0.7 million. The increase in expenses was primarily due to:
Depreciation and amortization were $2.1 million for the first quarter of 2020, as compared to $1.7 million for the same period in 2019, an increase of $0.4 million. The increase was driven primarily by increased depreciation expense on fixed assets.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accommodate, anniversary, attempt, avoid, await, back, bankruptcy, broke, burdened, chain, chance, clarity, clause, closure, Codification, communicating, comply, comprehensive, computation, computed, conformity, congregating, contact, covered, cure, deadline, dedicated, deducting, description, desire, developmental, direct, discovery, disruption, dividing, dosing, dynamic, economic, economy, emergence, employee, ensure, essential, event, evidence, evolution, exceed, experience, experienced, experiencing, expired, extraordinary, FDIC, fee, fight, fully, global, globally, governmental, health, healthcare, heavily, highly, home, ii, impairment, imposed, inevitable, Infantile, infringement, innovative, instability, interruption, investor, iv, justly, Juvenile, large, light, longer, lower, make, mitigate, monitor, monitoring, mutual, negligible, negotiate, nonclinical, offering, openly, opportunity, outstanding, oversight, pandemic, paramount, pause, paused, point, populated, predicated, prior, priority, progressing, progression, promptly, provision, public, quantified, raw, ready, reassessing, receipt, recommended, reconciling, recoverable, redirected, referenced, reinstated, rely, remote, renegotiate, represent, resume, running, safe, science, senior, shortly, shown, situation, social, spread, stand, strict, tenant, top, Topic, travel, unamortized, underwriting, underwritten, uninterrupted, VIITAL, virtual, warrant

Removed: accessing, accompany, add, adjusting, adjustment, advancement, agreed, Ahn, allegedly, alleging, Alvino, AMAG, announced, antidilutive, approving, arbitrate, arbitration, arbitrator, asserted, awarded, behalf, breach, breached, Buono, burn, calculation, Carsten, caution, cautionary, Chancery, cohort, collaborate, commencing, comparative, compel, complaint, constructive, correct, court, cumulative, decision, declaration, defendant, denied, determination, determined, disgorgement, dispute, District, Duyne, EB, EBMRF, EBRP, eliminate, enjoining, enriched, EPS, error, excessive, executed, execution, expansion, expectation, expressly, eye, FASB, February, fiduciary, Final, forward, foundation, Francisco, Frank, governance, hearing, hiring, historical, Howell, immaterial, improper, incorporating, initiate, inspect, intending, investigate, January, Jeffrey, joined, joint, Judgment, July, june, Junior, Law, Leland, lesser, lift, Mahon, Mark, match, meaningful, Medical, motion, MuGard, neurologic, nominal, Norgine, notice, October, oral, order, originally, package, Partnership, performed, permitted, preliminary, prepare, purportedly, purpose, qualified, recognition, record, refused, relate, reliance, Request, rich, Richard, Rouhandeh, scheduled, september, served, settle, settlement, Southern, stated, staying, Stefano, Stephen, Steven, stipulation, stockholder, submitted, subsequently, Thiel, Todd, transition, trust, undue, unjustly, upfront, Van, void, waste, week, Wider, William

From filing 10-Q 2020 Q1